Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $19.0 million.

  • Ultragenyx Pharmaceutical's Other Accumulated Expenses fell 35.59% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 35.59%. This contributed to the annual value of $19.0 million for FY2024, which is 39.00% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Accumulated Expenses of $19.0 million as of Q3 2025, which was down 9.17% from $20.9 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Other Accumulated Expenses high stood at $59.9 million for Q3 2022, and its period low was $19.0 million during Q3 2025.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Other Accumulated Expenses value was $29.4 million (recorded in 2024), while the average stood at $33.4 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Other Accumulated Expenses surged by 102.86% in 2022 and then slumped by 59.08% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Accumulated Expenses (Quarterly) stood at $42.1 million in 2021, then grew by 23.99% to $52.2 million in 2022, then slumped by 40.22% to $31.2 million in 2023, then crashed by 39.00% to $19.0 million in 2024, then crashed by 35.59% to $19.0 million in 2025.
  • Its last three reported values are $19.0 million in Q3 2025, $20.9 million for Q2 2025, and $20.6 million during Q1 2025.